Answers are grounded in this paper and cite their sources.
Background: MCT8 transports thyroid hormones into the central nervous system. A genetic deficiency of MCT8 leads to hypothyroidism in the brain and severe neurological symptoms, a condition known as Allan–Herndon–Dudley syndrome (AHDS). Replacing MCT8 with gene therapy could effectively treat AHDS, but the most suitable target cell is yet to be identified. Since endogenous Mct8 is expressed by the glial tanycytes that form the blood–cerebrospinal fluid barrier in the hypothalamus, we tested the efficacy of tanycyte-directed gene therapy. Methods: We used Mct8 −/− mice on an Oatp1c1 −/− background (double knockout, DKO) as a model of AHDS to avoid compensation of OATP1C1 for MCT8 deficiency. After DKO mice received an intracerebroventricular injection of an adeno-associated virus encoding Mct8 at postnatal day 40, we investigated endocrine and neurological parameters of the disease. Results: The gene therapy approach restored Mct8 expression and normalized thyrotropin releasing hormone-induced signaling in DKO tanycytes, suggesting intact MCT8 function in these cells. Although MCT8 rescue in tanycytes did not correct the overactive hypothalamus–pituitary–thyroid axis in DKO mice, it improved triiodothyronine concentrations and gene expression in the cortex. Furthermore, it counteracted the reduction in brain weight in DKO mice. Conclusions: Gene therapy targeting tanycytes improves neurological parameters in mice with Mct8 deficiency. Further research is needed to determine whether this approach could be used to treat AHDS.
No takes yet. Share an insight, caveat, or question.
Pereira et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: